Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

• Status: Completed
• Trial end date: 2008-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Diagnosis of probable AD according to the NINCDS-ADRDA criteria.

• Able to give informed consent. Patient' s caregiver must consent to participate in the study.

Exclusion Criteria:

• Use of medications for cognitive enhancement within 3 months of baseline.

• Significant neurologic disease other than AD that may affect cognition.